Silo Pharma Regains Nasdaq Compliance After Reverse Stock Split
Summary
Silo Pharma has regained compliance with Nasdaq's minimum bid price rule after its recent reverse stock split, removing the immediate threat of delisting, but a concurrent filing signals potential for significant future share dilution.
Key Events
-
Nasdaq Compliance Regained
The company received notification on June 17, 2026, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a bid price of $1.00 or greater for the required period.
-
Follows Reverse Stock Split
This compliance was achieved after a 1-for-15 reverse stock split, effective June 3, 2026, which boosted the per-share price.
-
Potential for Future Dilution
A concurrent PRE 14A filing indicates the company is seeking to increase its authorized common stock from 6.67 million to 250 million shares, suggesting significant potential for future capital raises and dilution.
Analysis
Silo Pharma successfully regained compliance with Nasdaq's minimum bid price requirement, a critical step to avoid delisting. This was achieved following a 1-for-15 reverse stock split that became effective on June 3, 2026. However, this positive development is immediately followed by a concurrent PRE 14A filing seeking shareholder approval to significantly increase authorized common stock, indicating potential for substantial future dilution.
At the time of this filing, SILO was trading at $6.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.32 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.